Mirikizumab + Mirikizumab + Tirzepatide + Placebo

Phase 3Recruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease, Obesity or Overweight

Trial Timeline

Jun 26, 2025 → May 1, 2028

NCT ID

NCT06937099

About Mirikizumab + Mirikizumab + Tirzepatide + Placebo

Mirikizumab + Mirikizumab + Tirzepatide + Placebo is a phase 3 stage product being developed by Eli Lilly for Crohn's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06937099. Target conditions include Crohn's Disease, Obesity or Overweight.

What happened to similar drugs?

9 of 20 similar drugs in Crohn's Disease were approved

Approved (9) Terminated (4) Active (11)

✅adalimumabAbbVieApproved

✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06937086	Phase 3	Recruiting	Jun 26, 2025	Apr 1, 2028	Ulcerative Colitis
NCT06937099	Phase 3	Recruiting	Jun 26, 2025	May 1, 2028	Crohn's Disease

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
E6011 + Placebo	Eisai	Phase 1	21
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Adalimumab + Placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33
placebo for risankizumab + risankizumab IV + risankizumab SC	AbbVie	Phase 3	40